Chemomab Therapeutics Statistics
Total Valuation
CMMB has a market cap or net worth of $8.40 million. The enterprise value is $1.72 million.
| Market Cap | 8.40M |
| Enterprise Value | 1.72M |
Important Dates
The next estimated earnings date is Thursday, November 19, 2026, before market open.
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CMMB has 7.25 million shares outstanding. The number of shares has increased by 34.42% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 7.25M |
| Shares Change (YoY) | +34.42% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 12.24% |
| Owned by Institutions (%) | 12.61% |
| Float | 5.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.41, with zero debt.
| Current Ratio | 6.41 |
| Quick Ratio | 6.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -82.17% and return on invested capital (ROIC) is -53.78%.
| Return on Equity (ROE) | -82.17% |
| Return on Assets (ROA) | -46.27% |
| Return on Invested Capital (ROIC) | -53.78% |
| Return on Capital Employed (ROCE) | -91.07% |
| Weighted Average Cost of Capital (WACC) | 8.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.52M |
| Employee Count | 3 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -62.46% in the last 52 weeks. The beta is 0.74, so CMMB's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -62.46% |
| 50-Day Moving Average | 1.90 |
| 200-Day Moving Average | 1.75 |
| Relative Strength Index (RSI) | 36.36 |
| Average Volume (20 Days) | 39,094 |
Short Selling Information
The latest short interest is 13,889, so 0.19% of the outstanding shares have been sold short.
| Short Interest | 13,889 |
| Short Previous Month | 10,544 |
| Short % of Shares Out | 0.19% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.91M |
| Pretax Income | -7.55M |
| Net Income | -7.55M |
| EBITDA | -7.85M |
| EBIT | -7.91M |
| Earnings Per Share (EPS) | -$1.01 |
Balance Sheet
The company has $6.69 million in cash and no debt, with a net cash position of $6.69 million or $0.92 per share.
| Cash & Cash Equivalents | 6.69M |
| Total Debt | n/a |
| Net Cash | 6.69M |
| Net Cash Per Share | $0.92 |
| Equity (Book Value) | 8.69M |
| Book Value Per Share | 1.20 |
| Working Capital | 8.40M |
Cash Flow
In the last 12 months, operating cash flow was -$8.73 million and capital expenditures -$6,000, giving a free cash flow of -$8.74 million.
| Operating Cash Flow | -8.73M |
| Capital Expenditures | -6,000 |
| Depreciation & Amortization | 58,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.74M |
| FCF Per Share | -$1.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CMMB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -34.42% |
| Shareholder Yield | -34.42% |
| Earnings Yield | -86.81% |
| FCF Yield | -103.94% |
Analyst Forecast
The average price target for CMMB is $15.00, which is 1,193.10% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.00 |
| Price Target Difference | 1,193.10% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 26, 2025. It was a reverse split with a ratio of 1:4.
| Last Split Date | Aug 26, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |